Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

• Revenue in USD (TTM)288.00k
• Net income in USD-218.13m
• Incorporated2010
• Employees96.00

• Location
  Viridian Therapeutics Inc221 CRESCENT STREET, BLDG. 17, SUITE 401WALTHAM 02453United StatesUSA
• Phone+1 (617) 272-4600
• Fax+1 (302) 655-5049
• Websitehttps://www.viridiantherapeutics.com/